GlassScriptPhysician profile
Robert John Sharkus
NPI 1841828837
$1,334.10
in general payments reported to CMS, 2019-2025
17 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $254.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $186.42 | 2025 | |
| Genentech USA, INC. | $168.10 | 2025 | Ocrevus, Ocrevus Zunovo |
| Biogen, INC. | $164.78 | 2025 | Tysabri, Vumerity, Leqembi |
| Emd Serono, INC. | $111.44 | 2025 | |
| Alexion Pharmaceuticals, INC. | $93.98 | 2025 | Ultomiris |
| Abbvie INC. | $85.89 | 2025 | |
| Amgen INC. | $51.53 | 2025 | Uplizna |
| Eisai INC. | $36.30 | 2025 | |
| Vanda Pharmaceuticals INC. | $32.29 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $25.80 | 2025 | Xeomin |
| Genentech, INC. | $23.80 | 2025 | Ocrevus |
| Impel Pharmaceuticals LLC | $22.59 | 2025 | Trudhesa |
| Ucb, INC. | $22.34 | 2025 | Rystiggo |
| Lundbeck LLC | $18.73 | 2025 | Vyepti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.95 | 2025 | Kisunla, Amyvid |
| Medtronic, INC. | $17.75 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sharkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.